Our panel of cell lines deliberately represented a heterogeneous collection of different glioma subtypes, including both IDH1-wildtype and IDH1-mutated cells lines as well as one line that exhibits high-level EGFR amplification and expresses EGFRvIII. The gene discussed is IDH1; the disease is central nervous system cancer.